Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Next Previous
X
Search
Trial Profile

A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 28 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sodium phenylbutyrate/ursodoxicoltaurine (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Pharmacokinetics
  • Sponsors Amylyx Pharmaceuticals

    • Most Recent Events

    • 29 Mar 2024 Results(n=11) assessing Pharmacokinetics and Pharmacodynamics of AMX0035 presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 15 Feb 2024 According to a Amylyx Pharmaceuticals media release, data from phase II a will be presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference on March 3-6, 2024 in Orlando, Florida.
    • 02 Oct 2023 According to a Amylyx Pharmaceuticals media release, the company announced that an abstract on data from this study has been accepted for the poster presentation at the hybrid 2023 Northeast ALS Consortium (NEALS) Annual Meeting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top